IGLCOR22-1

Across TCGA pan-cancer cohorts, IGLCOR22-1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGLCOR22-1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGLCOR22-1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGLCOR22-1 is over-expressed in tumor, although a few such as STAD and COAD show the opposite, repressed pattern.

LUAD, KIRC, and STAD are the cancer types where IGLCOR22-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLCOR22-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.228	<.001	6	view →
KIRC	All	III,IV	+0.091	.005	6	view →
STAD	Male	All	−0.694	.018	3	view →
COAD	Male	IV	−0.350	<.001	2	view →
BRCA	All	III,IV	−0.055	.034	2	view →
LUSC	Female	II,III,IV	+0.280	.004	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGLCOR22-1–LUAD

Open the LUAD breakdown →